Literature DB >> 24900525

Monitoring the distribution of warfarin in blood plasma.

Annika M Rosengren1, Björn C G Karlsson1, Ian A Nicholls2.   

Abstract

Warfarin is an anticoagulant drug extensively used in the treatment and prevention of thrombotic disorders. Previous studies have shown that warfarin binds extensively to blood plasma proteins and that only a small fraction of the drug is unbound and thus available for therapeutic function. Both warfarin's narrow therapeutic window and the susceptibility of anticoagulant function to patient-dependent factors necessitate regular monitoring. In this study, we have shown that the lifetimes for each of the various bound and free forms of the drug in blood plasma can be quantified in situ by time-correlated single-photon counting fluorescence spectroscopy over the clinically significant concentration range. A relationship between the blood coagulation and the distribution of fluorescence lifetimes was observed. The in situ detection of clinically relevant concentrations of warfarin in its respective bound and unbound forms could provide a prognostic tool for use in patient treatment.

Entities:  

Keywords:  TCSPC; coagulation; fluorescence spectroscopy; plasma; warfarin

Year:  2012        PMID: 24900525      PMCID: PMC4025853          DOI: 10.1021/ml300112e

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

1.  Measurement of warfarin in plasma by high performance liquid chromatography (HPLC) and its correlation with the international normalized ratio.

Authors:  Rossana Lombardi; Veena Chantarangkul; Marco Cattaneo; Armando Tripodi
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

2.  Warfarin: an environment-dependent switchable molecular probe.

Authors:  Ian A Nicholls; Björn C G Karlsson; Annika M Rosengren; Henning Henschel
Journal:  J Mol Recognit       Date:  2010 Nov-Dec       Impact factor: 2.137

3.  Synthetic human serum albumin Sudlow I binding site mimics.

Authors:  Björn C G Karlsson; Annika M Rosengren; Inga Näslund; Per Ola Andersson; Ian A Nicholls
Journal:  J Med Chem       Date:  2010-10-25       Impact factor: 7.446

4.  In situ detection of warfarin using time-correlated single-photon counting.

Authors:  Annika M Rosengren; Björn C G Karlsson; Inga Näslund; Per Ola Andersson; Ian A Nicholls
Journal:  Biochem Biophys Res Commun       Date:  2011-02-24       Impact factor: 3.575

5.  Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples.

Authors:  Mahasen A Radwan; Ghada A Bawazeer; Nouf M Aloudah; Bushra T AlQuadeib; Hassan Y Aboul-Enein
Journal:  Biomed Chromatogr       Date:  2011-03-04       Impact factor: 1.902

6.  Spectroscopic evidence for the presence of the cyclic hemiketal form of warfarin in aqueous solution: consequences for bioavailability.

Authors:  Annika M Rosengren; Björn C G Karlsson
Journal:  Biochem Biophys Res Commun       Date:  2011-03-05       Impact factor: 3.575

7.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 8.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.

Authors:  C S Landefeld; R J Beyth
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

9.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

10.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

View more
  3 in total

1.  Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro.

Authors:  Annamaria Lubelska; Gniewomir Latacz; Magdalena Jastrzębska-Więsek; Magdalena Kotańska; Rafał Kurczab; Anna Partyka; Małgorzata Anna Marć; Daria Wilczyńska; Agata Doroz-Płonka; Dorota Łażewska; Anna Wesołowska; Katarzyna Kieć-Kononowicz; Jadwiga Handzlik
Journal:  Molecules       Date:  2019-12-06       Impact factor: 4.411

2.  Consequences of morphology on molecularly imprinted polymer-ligand recognition.

Authors:  Annika M Rosengren; Björn C G Karlsson; Ian A Nicholls
Journal:  Int J Mol Sci       Date:  2013-01-09       Impact factor: 5.923

3.  Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.

Authors:  Zahra Molavi; Sara Razi; Seyed Amir Mirmotalebisohi; Amirjafar Adibi; Marzieh Sameni; Farshid Karami; Vahid Niazi; Zahra Niknam; Morteza Aliashrafi; Mohammad Taheri; Soudeh Ghafouri-Fard; Shabnam Jeibouei; Soodeh Mahdian; Hakimeh Zali; Mohammad Mehdi Ranjbar; Mohsen Yazdani
Journal:  Biomed Pharmacother       Date:  2021-03-31       Impact factor: 6.529

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.